

Julian Sevilla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5675089/publications.pdf>

Version: 2024-02-01

108
papers

2,982
citations

159358

30
h-index

197535

49
g-index

127
all docs

127
docs citations

127
times ranked

4144
citing authors

#	ARTICLE	IF	CITATIONS
1	Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. <i>New England Journal of Medicine</i> , 2020, 382, 1811-1822.	13.9	320
2	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. <i>Lancet Haematology</i> , 2015, 2, e315-e325.	2.2	146
3	Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. <i>Nature Medicine</i> , 2019, 25, 1396-1401.	15.2	117
4	Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. <i>Blood</i> , 2011, 117, 3759-3769.	0.6	108
5	Leukocyte adhesion deficiency-I: A comprehensive review of all published cases. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1418-1420.e10.	2.0	85
6	High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. <i>Journal of Neuro-Oncology</i> , 2005, 71, 33-38.	1.4	80
7	Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. <i>Bone Marrow Transplantation</i> , 2004, 33, 675-690.	1.3	71
8	A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. <i>Cytotherapy</i> , 2015, 17, 1594-1603.	0.3	69
9	Osmotic gradient ektacytometry: A valuable screening test for hereditary spherocytosis and other red blood cell membrane disorders. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 94-102.	0.7	67
10	KIR- α -HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. <i>Pediatric Blood and Cancer</i> , 2009, 53, 120-124.	0.8	64
11	NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia. <i>Cell Stem Cell</i> , 2019, 25, 607-621.e7.	5.2	64
12	Increasing Incidence of Invasive Aspergillosis in Pediatric Hematology Oncology Patients Over the Last Decade. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 642-646.	0.3	54
13	Therapeutic gene editing in $CD34^{+}$ hematopoietic progenitors from Fanconi anemia patients. <i>EMBO Molecular Medicine</i> , 2017, 9, 1574-1588.	3.3	54
14	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. <i>British Journal of Haematology</i> , 2018, 183, 110-118.	1.2	53
15	Chromosome fragility in patients with Fanconi anaemia: diagnostic implications and clinical impact. <i>Journal of Medical Genetics</i> , 2011, 48, 242-250.	1.5	51
16	A comprehensive strategy for the subtyping of patients with Fanconi anaemia: conclusions from the Spanish Fanconi Anemia Research Network. <i>Journal of Medical Genetics</i> , 2007, 44, 241-249.	1.5	47
17	Therapeutic embolization and surgical excision of haemophilic pseudotumour. <i>Haemophilia</i> , 1999, 5, 360-363.	1.0	45
18	Stem Cell Gene Therapy for Fanconi Anemia: Report from the 1st International Fanconi Anemia Gene Therapy Working Group Meeting. <i>Molecular Therapy</i> , 2011, 19, 1193-1198.	3.7	45

#	ARTICLE	IF	CITATIONS
19	Lentiviral-mediated Genetic Correction of Hematopoietic and Mesenchymal Progenitor Cells From Fanconi Anemia Patients. <i>Molecular Therapy</i> , 2009, 17, 1083-1092.	3.7	44
20	Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. <i>Experimental Hematology</i> , 2012, 40, 882-891.e1.	0.2	43
21	Engraftment and in vivo proliferation advantage of gene-corrected mobilized CD34+ cells from Fanconi anemia patients. <i>Blood</i> , 2017, 130, 1535-1542.	0.6	42
22	Worldwide study of hematopoietic allogeneic stem cell transplantation in pyruvate kinase deficiency. <i>Haematologica</i> , 2018, 103, e82-e86.	1.7	42
23	Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation. <i>Haematologica</i> , 2002, 87, 292-8.	1.7	41
24	Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. <i>Bone Marrow Transplantation</i> , 2012, 47, 1419-1427.	1.3	37
25	Transient donor cell-derived myelodysplastic syndrome with monosomy 7 after unrelated cord blood transplantation. <i>European Journal of Haematology</i> , 2006, 77, 259-263.	1.1	34
26	Graft Manipulation and Reduced-intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation From Mismatched Unrelated and Mismatched/Haploidentical Related Donors in Pediatric Leukemia Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, e85-e90.	0.3	34
27	Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors. <i>Leukemia Research</i> , 2017, 57, 60-64.	0.4	33
28	Malignant atrophic papulosis in an infant. <i>British Journal of Dermatology</i> , 2002, 146, 916-918.	1.4	32
29	Cerebral toxoplasmosis following etanercept treatment for idiopathic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). <i>Annals of Hematology</i> , 2003, 82, 649-653.	0.8	32
30	Generation of a High Number of Healthy Erythroid Cells from Gene-Edited Pyruvate Kinase Deficiency Patient-Specific Induced Pluripotent Stem Cells. <i>Stem Cell Reports</i> , 2015, 5, 1053-1066.	2.3	32
31	Risk Score for Pediatric Intensive Care Unit Admission in Children Undergoing Hematopoietic Stem Cell Transplantation and Analysis of Predictive Factors for Survival. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 526-531.	0.3	31
32	Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. <i>British Journal of Haematology</i> , 2009, 144, 909-916.	1.2	31
33	Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. <i>Current Gene Therapy</i> , 2017, 16, 338-348.	0.9	31
34	Granulocyte colony-stimulating factor alone at 12 μ g/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. <i>Bone Marrow Transplantation</i> , 2002, 30, 417-420.	1.3	30
35	High-dose Chemotherapy With Autologous Stem Cell Rescue as First Line of Treatment in Young Children with Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors. <i>Journal of Neuro-Oncology</i> , 2004, 67, 101-106.	1.4	30
36	Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. <i>European Journal of Haematology</i> , 2011, 87, 46-53.	1.1	29

#	ARTICLE	IF	CITATIONS
37	Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. <i>Bone Marrow Transplantation</i> , 2016, 51, 1211-1216.	1.3	29
38	Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation. <i>Annals of Hematology</i> , 2002, 81, 11-15.	0.8	27
39	Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 355-358.	1.3	27
40	Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2001, 28, 89-92.	1.3	26
41	Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. <i>Haematologica</i> , 2008, 93, 1278-1280.	1.7	26
42	Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. <i>Haematologica</i> , 2003, 88, 919-22.	1.7	25
43	Large volume leukapheresis in small children: safety profile and variables affecting peripheral blood progenitor cell collection. <i>Bone Marrow Transplantation</i> , 2003, 31, 263-267.	1.3	24
44	Analysis of Clinical Outcome and Survival in Pediatric Patients Undergoing Extracorporeal Photopheresis for the Treatment of Steroid-refractory GVHD. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 589-593.	0.3	24
45	Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2009, 95, 65-69.	1.4	22
46	Fatal Hepatic Failure Secondary to Acute Herpes Simplex Virus Infection. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 686-688.	0.3	21
47	Priming of Hematopoietic Progenitor Cells by Plerixafor and Filgrastim in Children With Previous Failure of Mobilization With Chemotherapy and/or Cytokine Treatment. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 146-150.	0.3	21
48	High resolution melting analysis for the identification of novel mutations in DKC1 and TERT genes in patients with dyskeratosis congenita. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 140-146.	0.6	21
49	Genetic analyses of aplastic anemia and idiopathic pulmonary fibrosis patients with short telomeres, possible implication of DNA-repair genes. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 82.	1.2	21
50	Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. <i>Bone Marrow Transplantation</i> , 2004, 34, 1051-1055.	1.3	20
51	Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2008, 10, 193-196.	0.7	19
52	Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency. <i>PLoS ONE</i> , 2019, 14, e0216674.	1.1	19
53	A Simplified Approach to Improve the Efficiency and Safety of Ex Vivo Hematopoietic Gene Therapy in Fanconi Anemia Patients. <i>Human Gene Therapy</i> , 2006, 17, 245-250.	1.4	18
54	Detectable clonal mosaicism in blood as a biomarker of cancer risk in Fanconi anemia. <i>Blood Advances</i> , 2017, 1, 319-329.	2.5	18

#	ARTICLE	IF	CITATIONS
55	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. <i>Journal of Medical Genetics</i> , 2020, 57, 258-268.	1.5	18
56	Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis. <i>Annals of Hematology</i> , 2001, 80, 456-459.	0.8	17
57	Engraftment Syndrome Emerges as the Main Cause of Transplant-Related Mortality in Pediatric Patients Receiving Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 492-496.	0.3	15
58	A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. <i>Bone Marrow Transplantation</i> , 2004, 34, 1077-1081.	1.3	14
59	Risks and methods for peripheral blood progenitor cell collection in small children. <i>Transfusion and Apheresis Science</i> , 2004, 31, 221-231.	0.5	14
60	HIGH-DOSE BUSULFAN AND MELPHALAN AS CONDITIONING REGIMEN FOR AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION IN HIGH-RISK EWING SARCOMA PATIENTS: A Long-Term Follow-Up Single-Center Study. <i>Pediatric Hematology and Oncology</i> , 2010, 27, 272-282.	0.3	14
61	Defining "poor mobilizer" in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. <i>Cytotherapy</i> , 2013, 15, 132-137.	0.3	14
62	Haploidentical or mismatched unrelated donor hematopoietic cell transplantation for Fanconi anemia: Results from the Severe Aplastic Anemia Working Party of the EBMT. <i>American Journal of Hematology</i> , 2021, 96, 571-579.	2.0	14
63	Successful Treatment of <i>Trichosporon beigelii</i> Pneumonia with Itraconazole. <i>Clinical Infectious Diseases</i> , 1998, 26, 999-1000.	2.9	13
64	Peripheral Blood Progenitor Cell Collection in Low-Weight Children. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 633-642.	1.8	13
65	Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using $\hat{I}^{\pm}I^2+$ T-Cell Receptor and CD19+ Cell Depleted Grafts: High CD56 ^{dim} /CD56 ^{bright} NK Cell Ratio Early Following Transplantation Is Associated With Lower Relapse Incidence and Better Outcome. <i>Frontiers in Immunology</i> , 2019, 10, 2504.	2.2	13
66	Natural gene therapy by reverse mosaicism leads to improved hematology in Fanconi anemia patients. <i>American Journal of Hematology</i> , 2021, 96, 989-999.	2.0	13
67	Chemotherapy-Related Secondary Acute Myeloid Leukemia in Patients Diagnosed With Osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 454-456.	0.3	12
68	ALLOGENEIC CORD BLOOD TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A Long-Term Follow-Up Single-Center Study. <i>Pediatric Hematology and Oncology</i> , 2009, 26, 165-174.	0.3	12
69	Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC). <i>Bone Marrow Transplantation</i> , 2020, 55, 1744-1753.	1.3	12
70	Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. <i>Bone Marrow Transplantation</i> , 2005, 35, S17-S21.	1.3	11
71	PBSC collection in extremely low weight infants: a single-center experience. <i>Cytotherapy</i> , 2007, 9, 356-361.	0.3	11
72	Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic stem cell transplantation in childhood leukaemia patients. <i>British Journal of Haematology</i> , 2008, 140, 340-343.	1.2	10

#	ARTICLE	IF	CITATIONS
73	DÃ©ficit de piruvato cinasa eritrocitaria en EspaÃ±a: estudio de 15 casos. Medicina ClÃ©nica, 2017, 148, 23-27.	0.3	10
74	Improved collection of hematopoietic stem cells and progenitors from Fanconi anemia patients for gene therapy purposes. Molecular Therapy - Methods and Clinical Development, 2021, 22, 66-75.	1.8	10
75	Severe systemic autoimmune disease associated with Epstein-Barr virus infection. Journal of Pediatric Hematology/Oncology, 2004, 26, 831-3.	0.3	6
76	Early onset of acute immune-mediated lung injury in a child undergoing allogeneic peripheral blood transplantation. American Journal of Hematology, 2002, 69, 56-58.	2.0	5
77	Successful Treatment of Invasive Aspergillosis With Oral Voriconazole Following Intravenous Liposomal Amphotericin in a Child With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2004, 26, 117-119.	0.3	5
78	Pyruvate kinase deficiency and severe congenital hemolytic anemia in a double heterozygous patient with paternal transmission of an early germâ€”line <i>de novo</i> mutation. American Journal of Hematology, 2015, 90, E217-9.	2.0	5
79	Clinical and economic evaluation of using granulocyte colony-stimulating factor after autologous peripheral blood progenitor cell transplantation in children. Haematologica, 2002, 87, 105-6.	1.7	5
80	Dyspnea as the first manifestation of primary pancreatic lymphoma. Pediatric Blood and Cancer, 2008, 50, 434-434.	0.8	4
81	Compassionate Use Study of Caspofungin in Children with Proven or Suspected Invasive Mycosis or Persistent Febrile Neutropenia. Journal of Chemotherapy, 2009, 21, 229-231.	0.7	4
82	Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients. Blood, 2021, 138, 563-563.	0.6	4
83	Early Acute Myeloblastic Leukemia Treatment for Childhood Myelodysplastic Syndrome With t(3;5) (NPM/MLF1). Journal of Pediatric Hematology/Oncology, 2007, 29, 839-840.	0.3	3
84	Pulmonary Glial Heterotopia in a Child Diagnosed With Fanconi Anemia and Epilepsy. Journal of Pediatric Hematology/Oncology, 2011, 33, 462-464.	0.3	3
85	Hb Cibeles [α^2 CD25(B6) (Glyâ€”Asp)]: a novel alpha chain variant causing alpha-thalassemia. International Journal of Hematology, 2014, 100, 599-601.	0.7	3
86	Plerixaforâ€”based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better ^{CD34}+<sup> collection yield: A retrospective analysis. Journal of Clinical Apheresis, 2021, 36, 78-86.	0.7	3
87	Variables related to chronic immune thrombocytopenia: experience from a single center and comparison to a meta-analysis. European Journal of Pediatrics, 2021, 180, 2075-2081.	1.3	3
88	Graft failure after â€”ex-vivoâ€”T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis. Leukemia and Lymphoma, 2021, 62, 1-8.	0.6	3
89	Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (^{PKD}): Toward an expanded definition of severe ^{PKD}. American Journal of Hematology, 2022, 97, .	2.0	3
90	Varicella zoster central nervous system vasculitis after allogeneic hematopoietic stem cell transplant successfully treated with cyclophosphamide. Transplant Infectious Disease, 2012, 14, E107-10.	0.7	2

#	ARTICLE	IF	CITATIONS
91	Using Rheopheresis for stem cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). <i>Transfusion and Apheresis Science</i> , 2013, 49, 234-237.	0.5	2
92	IgA-Mediated Autoimmune Hemolytic Anemia: A Clinical Conundrum. <i>Pediatric Blood and Cancer</i> , 2016, 63, 754-754.	0.8	2
93	Anemias raras y fallos medulares hereditarios. <i>Arbor</i> , 2018, 194, 463.	0.1	2
94	A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. <i>Leukemia</i> , 2021, 35, 3295-3298.	3.3	2
95	Upregulation of NKG2D ligands impairs hematopoietic stem cell function in Fanconi anemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	2
96	Hemiparesis in an Adolescent With Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 63-64.	0.3	1
97	Immunomagnetic T Cell Depletion: an Analysis of Variables Affecting Final Cell Yield. <i>Clinical Laboratory</i> , 2016, 62, 1243-1248.	0.2	1
98	Mobilization with high-dose granulocyte colony-stimulating factor alone at 12µg/kg twice a day in high-risk pediatric patients: A retrospective analysis of the experience in a single center. <i>Journal of Clinical Apheresis</i> , 2022, 37, 420-429.	0.7	1
99	T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCR β 12+/CD19+ Depletion Platforms. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
100	Extramedullary acute lymphoblastic leukaemia in childhood. <i>European Journal of Haematology</i> , 2007, 79, 182-182.	1.1	0
101	AfÃ©resis en PediatrÃ­a. <i>Anales De PediatrÃ­a Continuada</i> , 2014, 12, 256-259.	0.0	0
102	Outcome and Prognostic Factors for Pediatric Patients Receiving an Haploidentical Transplantation Using CD3/CD19 Depleted Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S33.	2.0	0
103	Protocolo diagnÃ³stico y tratamiento de la anemia microcÃ©tica en el adolescente. <i>Medicine</i> , 2018, 12, 3613-3618.	0.0	0
104	Vox Sanguinis International Forum on paediatric indications for blood component transfusion. <i>Vox Sanguinis</i> , 2019, 114, e36-e90.	0.7	0
105	Management of primary immune thrombocytopenia. A comparison between two historical cohorts. <i>Anales De PediatrÃ­a (English Edition)</i> , 2021, 95, 86-92.	0.1	0
106	DiagnÃ³stico y tratamiento de la trombocitemia esencial en la edad pediÃ¡trica. , 2013, , 27-33.		0
107	NHEJ-Mediated Gene Editing: An Efficient Approach to Correct Mutations in Hematopoietic Stem and Progenitor Cells from Patients with Fanconi Anemia. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
108	<i>Letter to the Editor:</i> Hematopoietic Stem and Progenitor Cell Mobilization and Collection for Patients Diagnosed with Osteopetrosis and Hurler Syndrome. <i>Human Gene Therapy</i> , 2022, 33, 213-214.	1.4	0